Ralaniten
Chemical compound
Clinical data | |
---|---|
Other names | EPI-002 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C21H27ClO5 |
Molar mass | 394.89 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
See also
References
- ^ a b Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. (July 2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation. 123 (7): 2948–2960. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
- ^ Monaghan AE, McEwan IJ (2016). "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687–694. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
- ^ Maughan BL, Antonarakis ES (December 2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Current Treatment Options in Oncology. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882. S2CID 30398927.
- v
- t
- e
Agonists |
|
---|
- See also
- Receptor/signaling modulators
- Androgens and antiandrogens
- Estrogen receptor modulators
- Progesterone receptor modulators
- List of androgens and anabolic steroids
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e